Janney Montgomery Scott’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$1.72M Buy
13,698
+830
+6% +$104K ﹤0.01% 1285
2025
Q1
$1.42M Sell
12,868
-4,677
-27% -$517K ﹤0.01% 1326
2024
Q4
$2.4M Buy
17,545
+1,150
+7% +$157K 0.01% 1075
2024
Q3
$1.89M Sell
16,395
-413
-2% -$47.6K 0.01% 1165
2024
Q2
$2.31M Buy
16,808
+7,901
+89% +$1.09M 0.01% 1037
2024
Q1
$1.23M Buy
8,907
+270
+3% +$37.2K ﹤0.01% 1414
2023
Q4
$1.14M Buy
8,637
+4,030
+87% +$531K ﹤0.01% 1376
2023
Q3
$518K Buy
4,607
+348
+8% +$39.1K ﹤0.01% 1744
2023
Q2
$402K Sell
4,259
-44,204
-91% -$4.17M ﹤0.01% 2028
2023
Q1
$4.91M Buy
48,463
+3,460
+8% +$350K 0.02% 647
2022
Q4
$5.38M Buy
45,003
+41,119
+1,059% +$4.91M 0.02% 648
2022
Q3
$413K Buy
3,884
+1,675
+76% +$178K ﹤0.01% 1810
2022
Q2
$215K Sell
2,209
-1,062
-32% -$103K ﹤0.01% 2099
2022
Q1
$307K Sell
3,271
-166
-5% -$15.6K ﹤0.01% 1873
2021
Q4
$293K Sell
3,437
-12,334
-78% -$1.05M ﹤0.01% 2013
2021
Q3
$1.51M Buy
15,771
+799
+5% +$76.6K 0.01% 1080
2021
Q2
$1.46M Sell
14,972
-2,784
-16% -$271K 0.01% 1090
2021
Q1
$1.73M Buy
17,756
+12,373
+230% +$1.2M 0.01% 954
2020
Q4
$516K Sell
5,383
-7,247
-57% -$695K ﹤0.01% 1552
2020
Q3
$1.22M Buy
12,630
+742
+6% +$71.4K 0.01% 1008
2020
Q2
$1.45M Buy
11,888
+172
+1% +$21K 0.01% 881
2020
Q1
$1.01M Buy
11,716
+1,198
+11% +$104K 0.01% 927
2019
Q4
$1.13M Sell
10,518
-653
-6% -$70.2K 0.01% 1019
2019
Q3
$1.01M Buy
11,171
+309
+3% +$27.9K 0.01% 1036
2019
Q2
$917K Buy
10,862
+1,545
+17% +$130K 0.01% 1097
2019
Q1
$821K Buy
+9,317
New +$821K 0.01% 1128
2016
Q4
Sell
-8,924
Closed -$452K 1711
2016
Q3
$452K Buy
+8,924
New +$452K 0.01% 1013
2016
Q2
Sell
-8,924
Closed -$353K 998
2016
Q1
$353K Sell
8,924
-1,096
-11% -$43.4K 0.01% 897
2015
Q4
$567K Hold
10,020
0.01% 765
2015
Q3
$399K Buy
10,020
+596
+6% +$23.7K 0.01% 936
2015
Q2
$450K Buy
9,424
+2,023
+27% +$96.6K 0.01% 1239
2015
Q1
$294K Buy
+7,401
New +$294K 0.01% 1783